Last update Jan. 30, 2021
Very Low Risk
Short-acting anticholinergic, specific antagonist of muscarinic receptors, which inhibits the bronchoconstrictive effects of acetylcholine.
Indicated in the treatment of asthma.
At latest update no published data on excretion into breastmilk were found.
Because of a large volume of distribution along with a very low or undetectable plasma concentration reached after inhalation (Boehringer 2015, AEMPS 2013, Laurikainen 1988, Wood 1995), it must be very unlikely the passage of significant amounts into breastmilk.
Its low oral bioavailability would hamper the pass to the infant’s plasma through the breastmilk ingested (AEMPS 2013).
It has been used to treat newborns (Pediamecum 2015).
Experts and scientific societies consider the use of ipratropium bromide during breastfeeding as devoid of risk to the infant (Hale, Lactmed, Amir 2011, National Asthma Education 2004, van Haren 1998).
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM